ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Manisha Khandait1 , Ishi Sharma2 and Rakesh Pandit3
1Department of Microbiology, Shree Guru Gobind Singh Tricentenary University,
Budhera Gurgaon – 110075, India.
2Department of Pathology, Aakash Pathlab, Aakash Healthcare Super Speciality Hospital,
Dwarka, New Delhi, India.
3Department of Internal Medicine, Aakash Healthcare Super Speciality Hospital, Dwarka, New Delhi, India.
J Pure Appl Microbiol. 2021;15(2):819-825 | Article Number: 6852 | © The Author(s). 2021
Received: 13/01/2021 | Accepted: 07/05/2021 | Published: 28/05/2021

Elevated or abnormal levels of coagulation parameters indicate thrombotic disorders that need to be managed at the earliest to prevent complications and reduce mortality in coronavirus disease (COVID-19) patients. D-dimer is a product that is a part of fibrin abasement, which can be used as a test for the diagnosis of thrombotic disorders. Higher D-dimer levels are a strong indicator of mortality in patients with active COVID-19. This study aimed to determine the relationship between D-dimer levels and the clinical prognosis of COVID-19 patients. This observational, prospective study was conducted between April 2020 and September 2020. All patients with COVID-19 infection were considered for this study, along with their D-dimer values. Patients with higher D-dimer levels and pre-existing morbidities experienced a longer hospital stay and increased complications when compared to patients without pre-existing morbidities. Abnormally elevated D-dimer levels were frequently observed upon admission due to COVID-19 and are analogous to the increased occurrence of critical illness, thrombotic events, acute kidney injury, and death. Therefore, D-dimer levels could be a valuable clinical biomarker and an important indicator of prognosis for patients with COVID-19 with pre-existing morbidities.


COVID-19, Coronavirus, D-Dimer, Hypercoagulation, Prognosis, Mortality

Article Metrics

Article View: 665

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.